BiotechTube
TeselaGen Biotechnology

TeselaGen Biotechnology

San Francisco, United States· Est.
teselagen.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $16.5M

Overview

TeselaGen provides an enterprise AI operating system for biotechnology, enabling researchers to close DBTL cycles up to 10x faster. Its platform features specialized AI agents for tasks like combinatorial library design, assembly protocol optimization, and experiment iteration, powered by a proprietary machine learning engine called Synthetic Evolution. The company targets a broad market from academic researchers to large pharmaceutical companies with a SaaS model, integrating seamlessly with common lab equipment and software to streamline R&D workflows.

AI / Machine Learning

Technology Platform

Tesela AI platform featuring specialized AI agents for the DBTL cycle, including a Library Designer, Library Construction Optimizer, and an Experiment Optimizer powered by the patented Synthetic Evolution® machine learning engine. Integrates with lab hardware and software via REST API and Python SDK.

Funding History

3
Total raised:$16.5M
Series B$10M
Series A$5M
Seed$1.5M

Opportunities

The massive digitization and automation of biotech R&D creates a large market for AI-driven design and workflow software.
Expansion into new application areas like cell therapy, gene therapy, and mRNA design presents significant growth potential.
The enterprise SaaS model offers scalable, recurring revenue from large pharmaceutical and industrial biotech companies.

Risk Factors

Faces competition from established ELN/LIMS providers expanding into AI and new AI-native startups.
Success is partially dependent on the adoption rate of lab automation hardware.
Risks include AI model accuracy, data security for sensitive IP, and the challenge of demonstrating clear, measurable ROI to secure and retain enterprise customers.

Competitive Landscape

TeselaGen competes in the growing market for AI-powered biotech software. Key competitors include Benchling (broad ELN/R&D platform with increasing AI features), other AI-driven design tools like Atomwise or Insilico Medicine (more focused on small molecule/drug discovery), and automation software suites from instrument vendors. Its differentiation lies in its specialized agents for the full DBTL cycle and deep integration with physical lab automation.

More companies in Synthetic Biology →More companies in United States →